Use of the Janssen (Johnson & Johnson) COVID-19 Vaccine: Updated Interim Recommendations from the Advisory Committee on Immunization Practices - United States, December 2021
- PMID: 35051137
- PMCID: PMC8774160
- DOI: 10.15585/mmwr.mm7103a4
Use of the Janssen (Johnson & Johnson) COVID-19 Vaccine: Updated Interim Recommendations from the Advisory Committee on Immunization Practices - United States, December 2021
Abstract
On February 27, 2021, the Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) for the adenovirus-vectored COVID-19 vaccine (Janssen Biotech, Inc., a Janssen Pharmaceutical company, Johnson & Johnson), and on February 28, 2021, the Advisory Committee on Immunization Practices (ACIP) issued an interim recommendation for its use as a single-dose primary vaccination in persons aged ≥18 years (1,2). On April 13, 2021, CDC and FDA recommended a pause in the use of Janssen COVID-19 vaccine after reports of thrombosis with thrombocytopenia syndrome (TTS), a rare condition characterized by low platelets and thrombosis, including at unusual sites such as the cerebral venous sinus (cerebral venous sinus thrombosis [CVST]), after receipt of the vaccine.* ACIP rapidly convened two emergency meetings to review reported cases of TTS, and 10 days after the pause commenced, ACIP reaffirmed its interim recommendation for use of the Janssen COVID-19 vaccine in persons aged ≥18 years, but included a warning regarding rare clotting events after vaccination, primarily among women aged 18-49 years (3). In July, after review of an updated benefit-risk assessment accounting for risks of Guillain-Barré syndrome (GBS) and TTS, ACIP concluded that benefits of vaccination with Janssen COVID-19 vaccine outweighed risks. Through ongoing safety surveillance and review of reports from the Vaccine Adverse Event Reporting System (VAERS), additional cases of TTS after receipt of Janssen COVID-19 vaccine, including deaths, were identified. On December 16, 2021, ACIP held an emergency meeting to review updated data on TTS and an updated benefit-risk assessment. At that meeting, ACIP made a recommendation for preferential use of mRNA COVID-19 vaccines over the Janssen COVID-19 vaccine, including both primary and booster doses administered to prevent COVID-19, for all persons aged ≥18 years. The Janssen COVID-19 vaccine may be considered in some situations, including for persons with a contraindication to receipt of mRNA COVID-19 vaccines.
Conflict of interest statement
All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. Allison Lale reports personal fees from the Medical Library Association, outside the submitted work. No other potential conflicts of interest were disclosed.
Similar articles
-
Updated Recommendations from the Advisory Committee on Immunization Practices for Use of the Janssen (Johnson & Johnson) COVID-19 Vaccine After Reports of Thrombosis with Thrombocytopenia Syndrome Among Vaccine Recipients - United States, April 2021.MMWR Morb Mortal Wkly Rep. 2021 Apr 30;70(17):651-656. doi: 10.15585/mmwr.mm7017e4. MMWR Morb Mortal Wkly Rep. 2021. PMID: 33914723 Free PMC article.
-
Safety Monitoring of the Janssen (Johnson & Johnson) COVID-19 Vaccine - United States, March-April 2021.MMWR Morb Mortal Wkly Rep. 2021 May 7;70(18):680-684. doi: 10.15585/mmwr.mm7018e2. MMWR Morb Mortal Wkly Rep. 2021. PMID: 33956784 Free PMC article.
-
Use of COVID-19 Vaccines After Reports of Adverse Events Among Adult Recipients of Janssen (Johnson & Johnson) and mRNA COVID-19 Vaccines (Pfizer-BioNTech and Moderna): Update from the Advisory Committee on Immunization Practices - United States, July 2021.MMWR Morb Mortal Wkly Rep. 2021 Aug 13;70(32):1094-1099. doi: 10.15585/mmwr.mm7032e4. MMWR Morb Mortal Wkly Rep. 2021. PMID: 34383735 Free PMC article.
-
A summary of the Advisory Committee for Immunization Practices (ACIP) use of a benefit-risk assessment framework during the first year of COVID-19 vaccine administration in the United States.Vaccine. 2023 Oct 20;41(44):6456-6467. doi: 10.1016/j.vaccine.2023.07.037. Epub 2023 Jul 30. Vaccine. 2023. PMID: 37527956 Free PMC article. Review.
-
Post-authorization safety surveillance of Ad.26.COV2.S vaccine: Reports to the Vaccine Adverse Event Reporting System and v-safe, February 2021-February 2022.Vaccine. 2023 Jul 5;41(30):4422-4430. doi: 10.1016/j.vaccine.2023.06.023. Epub 2023 Jun 14. Vaccine. 2023. PMID: 37321898 Free PMC article. Review.
Cited by
-
Psychological reactance, misinformation, and distrust: A mixed methods analysis of COVID-19 vaccine uptake.J Clin Transl Sci. 2024 Jan 30;8(1):e48. doi: 10.1017/cts.2024.15. eCollection 2024. J Clin Transl Sci. 2024. PMID: 38510694 Free PMC article.
-
Autoimmune disorders reported following COVID-19 vaccination: A disproportionality analysis using the WHO database.Eur J Clin Pharmacol. 2024 Mar;80(3):445-453. doi: 10.1007/s00228-023-03618-w. Epub 2024 Jan 12. Eur J Clin Pharmacol. 2024. PMID: 38212538
-
COVID-19 Vaccines in Children.J Clin Med. 2023 Dec 23;13(1):87. doi: 10.3390/jcm13010087. J Clin Med. 2023. PMID: 38202094 Free PMC article. Review.
-
Post-Vaccination Syndrome: A Descriptive Analysis of Reported Symptoms and Patient Experiences After Covid-19 Immunization.medRxiv [Preprint]. 2023 Nov 10:2023.11.09.23298266. doi: 10.1101/2023.11.09.23298266. medRxiv. 2023. PMID: 37986769 Free PMC article. Preprint.
-
Blood Coagulation and Thrombotic Disorders following SARS-CoV-2 Infection and COVID-19 Vaccination.Biomedicines. 2023 Oct 17;11(10):2813. doi: 10.3390/biomedicines11102813. Biomedicines. 2023. PMID: 37893186 Free PMC article. Review.
References
-
- Food and Drug Administration. Janssen COVID-19 vaccine emergency use authorization. Silver Spring, MD: US Department of Health and Human Services, Food and Drug Administration; 2021. https://www.fda.gov/emergency-preparedness-and-response/coronavirus-dise...
-
- MacNeil JR, Su JR, Broder KR, et al. Updated recommendations from the Advisory Committee on Immunization Practices for use of the Janssen (Johnson & Johnson) COVID-19 vaccine after reports of thrombosis with thrombocytopenia syndrome among vaccine recipients—United States, April 2021. MMWR Morb Mortal Wkly Rep 2021;70:651–6. 10.15585/mmwr.mm7017e4 - DOI - PMC - PubMed
-
- Rosenblum HG, Hadler SC, Moulia D, et al. Use of COVID-19 vaccines after reports of adverse events among adult recipients of Janssen (Johnson & Johnson) and mRNA COVID-19 vaccines (Pfizer-BioNTech and Moderna): update from the Advisory Committee on Immunization Practices—United States, July 2021. MMWR Morb Mortal Wkly Rep 2021;70:1094–9. 10.15585/mmwr.mm7032e4 - DOI - PMC - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous